Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents
Abstract Introduction Although the combination of venetoclax (VEN) and hypomethylating agents (HMAs) results in impressive efficacy in acute myeloid leukemia (AML), there is still a subset of patients who are refractory. We investigated the outcomes of AML patients with monocytic differentiation who...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-07-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.7378 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850122836685881344 |
|---|---|
| author | Dian Jin Jingsong He Haoguang Chen Wenjun Wu Xiaoyan Han Jing Le Wenxiu Shu Qianqian Yang Shanshan Pei Zhen Cai Donghua He |
| author_facet | Dian Jin Jingsong He Haoguang Chen Wenjun Wu Xiaoyan Han Jing Le Wenxiu Shu Qianqian Yang Shanshan Pei Zhen Cai Donghua He |
| author_sort | Dian Jin |
| collection | DOAJ |
| description | Abstract Introduction Although the combination of venetoclax (VEN) and hypomethylating agents (HMAs) results in impressive efficacy in acute myeloid leukemia (AML), there is still a subset of patients who are refractory. We investigated the outcomes of AML patients with monocytic differentiation who were treated with frontline VEN/HMA. Methods A total of 155 patients with newly diagnosed AML treated with frontline VEN/HMA were enrolled in the study. Monocyte‐like AML was identified by flow cytometry with typical expression of monocytic markers, and M5 was identified according to French, American, and British category. We compared the outcomes of patients with different characteristics. Results The rate of complete remission (CR) and CR with incomplete recovery of blood counts (CRi), progression‐free survival (PFS), and overall survival (OS) in monocyte‐like AML were inferior to those in nonmonocyte‐like AML (CR/CRi rates, 26.7% vs. 80.0%, p < 0.001; median PFS, 2.1 vs. 8.8 months, p < 0.001; median OS, 9.2 vs. 19 months, p = 0.013). CR/CRi rate in M5 was lower than that in non‐M5 (60.7% vs. 75.5%, p = 0.049). Multivariate analyses showed that monocyte‐like AML was associated with lower odds of CR/CRi and higher risk of progression. Conclusion Our study suggested that newly diagnosed AML with a monocytic immunophenotype had a poor prognosis with VEN/HMA treatment. |
| format | Article |
| id | doaj-art-171672d2f85c402e80efd150e75e519a |
| institution | OA Journals |
| issn | 2045-7634 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-171672d2f85c402e80efd150e75e519a2025-08-20T02:34:44ZengWileyCancer Medicine2045-76342024-07-011314n/an/a10.1002/cam4.7378Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agentsDian Jin0Jingsong He1Haoguang Chen2Wenjun Wu3Xiaoyan Han4Jing Le5Wenxiu Shu6Qianqian Yang7Shanshan Pei8Zhen Cai9Donghua He10Bone Marrow Transplantation Center, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou ChinaBone Marrow Transplantation Center, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou ChinaBone Marrow Transplantation Center, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou ChinaBone Marrow Transplantation Center, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou ChinaBone Marrow Transplantation Center, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou ChinaDepartment of Hematology Ningbo Medical Treatment Center Li Huili Hospital Ningbo ChinaDepartment of Hematology Ningbo Medical Treatment Center Li Huili Hospital Ningbo ChinaDepartment of Hematology Ningbo Medical Treatment Center Li Huili Hospital Ningbo ChinaBone Marrow Transplantation Center, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou ChinaBone Marrow Transplantation Center, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou ChinaBone Marrow Transplantation Center, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou ChinaAbstract Introduction Although the combination of venetoclax (VEN) and hypomethylating agents (HMAs) results in impressive efficacy in acute myeloid leukemia (AML), there is still a subset of patients who are refractory. We investigated the outcomes of AML patients with monocytic differentiation who were treated with frontline VEN/HMA. Methods A total of 155 patients with newly diagnosed AML treated with frontline VEN/HMA were enrolled in the study. Monocyte‐like AML was identified by flow cytometry with typical expression of monocytic markers, and M5 was identified according to French, American, and British category. We compared the outcomes of patients with different characteristics. Results The rate of complete remission (CR) and CR with incomplete recovery of blood counts (CRi), progression‐free survival (PFS), and overall survival (OS) in monocyte‐like AML were inferior to those in nonmonocyte‐like AML (CR/CRi rates, 26.7% vs. 80.0%, p < 0.001; median PFS, 2.1 vs. 8.8 months, p < 0.001; median OS, 9.2 vs. 19 months, p = 0.013). CR/CRi rate in M5 was lower than that in non‐M5 (60.7% vs. 75.5%, p = 0.049). Multivariate analyses showed that monocyte‐like AML was associated with lower odds of CR/CRi and higher risk of progression. Conclusion Our study suggested that newly diagnosed AML with a monocytic immunophenotype had a poor prognosis with VEN/HMA treatment.https://doi.org/10.1002/cam4.7378acute myeloid leukemiacancer risk factorprognosistargeted therapy |
| spellingShingle | Dian Jin Jingsong He Haoguang Chen Wenjun Wu Xiaoyan Han Jing Le Wenxiu Shu Qianqian Yang Shanshan Pei Zhen Cai Donghua He Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents Cancer Medicine acute myeloid leukemia cancer risk factor prognosis targeted therapy |
| title | Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents |
| title_full | Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents |
| title_fullStr | Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents |
| title_full_unstemmed | Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents |
| title_short | Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents |
| title_sort | impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents |
| topic | acute myeloid leukemia cancer risk factor prognosis targeted therapy |
| url | https://doi.org/10.1002/cam4.7378 |
| work_keys_str_mv | AT dianjin impactofmonocyticdifferentiationonacutemyeloidleukemiapatientstreatedwithvenetoclaxandhypomethylatingagents AT jingsonghe impactofmonocyticdifferentiationonacutemyeloidleukemiapatientstreatedwithvenetoclaxandhypomethylatingagents AT haoguangchen impactofmonocyticdifferentiationonacutemyeloidleukemiapatientstreatedwithvenetoclaxandhypomethylatingagents AT wenjunwu impactofmonocyticdifferentiationonacutemyeloidleukemiapatientstreatedwithvenetoclaxandhypomethylatingagents AT xiaoyanhan impactofmonocyticdifferentiationonacutemyeloidleukemiapatientstreatedwithvenetoclaxandhypomethylatingagents AT jingle impactofmonocyticdifferentiationonacutemyeloidleukemiapatientstreatedwithvenetoclaxandhypomethylatingagents AT wenxiushu impactofmonocyticdifferentiationonacutemyeloidleukemiapatientstreatedwithvenetoclaxandhypomethylatingagents AT qianqianyang impactofmonocyticdifferentiationonacutemyeloidleukemiapatientstreatedwithvenetoclaxandhypomethylatingagents AT shanshanpei impactofmonocyticdifferentiationonacutemyeloidleukemiapatientstreatedwithvenetoclaxandhypomethylatingagents AT zhencai impactofmonocyticdifferentiationonacutemyeloidleukemiapatientstreatedwithvenetoclaxandhypomethylatingagents AT donghuahe impactofmonocyticdifferentiationonacutemyeloidleukemiapatientstreatedwithvenetoclaxandhypomethylatingagents |